Baturin V A, Shchetinin E V, Malykhin F T
Stavropol State Medical University of the Ministry of Health, Russian Federation, Department of Clinical Pharmacology, Allergy and Immunology, Stavropol, Russia.
Stavropol State Medical University of the Ministry of Health, Russian Federation, Pathological Physiology, Stavropol, Russia.
Int J Risk Saf Med. 2015;27 Suppl 1:S61-2. doi: 10.3233/JRS-150691.
The last years have witnessed progressive growth of antimicrobial resistance (AMR) both in hospital-acquired and community-acquired respiratory infections. Regional guidelines (2006) presented standard approaches to pharmacotherapy and provided an important contribution to improvement of antimicrobial therapy at healthcare facilities of both the City of Stavropol and the Stavropol Region. At the same time, recent years have witnessed substantial changes in sensitivity to antimicrobials; besides, newer antibiotics have become available now. This substantiates the need for update of the regional guidelines [1].
To determine the issues related to standardization of antibiotic therapy of lower respiratory tract (LRT) infections at an outpatient setting; to assess regional changes (2007-2012) in the spectrum of pathogens causing LRT diseases in patients of the regional healthcare facilities in view of their age and the diagnosis as compared with the years of 2003-2006.
In 2007-2012, we examined sputum microbiology of patients with LRT infections at the bacteriological laboratory of the Centre for Clinical Pharmacology and Pharmacotherapy (Stavropol, Russia), following the methodology guidelines [2]. The comparison was carried out with the results of the microbiological examination of 7051 sputum samples (held in 2003-2006). Statistical analysis was carried out using arithmetic means, standard errors, and Student's t test involving a software package STATISTICA 6.0.
In the outpatient practice, half of the patients with LRT infections were identified to have Str. Pneumoniae. The sputum of every fifth examined patient allowed isolating Enterobacteriaceae family members such as Klebsiella spp. (Klebsiella pneumoniae in most cases), Serratiaspp., E. coli, and Enterobacter spp. It is essential to note that almost a quarter of the patients were found to have M. pneumoniae. C. Pneumonia was detected quite often as well (19%). Str. pneumoniae, M. pneumoniae, and C. pneumoniae were found in virtually 80% of all the cases of community-acquired pneumonia in adults. H. influenzae and M. pneumoniae were 2-3 times more often isolated from the sputum of patients with chronic obstructive pulmonary disease (COPD) and chronic non-obstructive bronchitis.Along with an increase in the patients' age, regardless of the diagnosis, the proportion of pneumococci, Haemophilus influenzae and various members of the Enterobacteriaceae family went up, while the share of mycoplasmas went down. However, even in patients over 60 years of age M. pneumoniae accounted for a significant share in the overall spectrum of pathogens, which indicates the need for microbiological monitoring, especially as far as COPD is concerned.In contrast to the previous years, only 35% of the patients (previously 60%) underwent bacteriological examination (p<0.05) while receiving antibiotic therapy. Significant prevalence of mycoplasmas in the structure of the isolated microorganisms was found in patients who had been previously treated with β-lactam antibiotics.Associations of pathogens were detected in 14% of cases, which is half the rate found 2-3 years ago. The associations were found to reveal more frequent presence of H. influenzae in patients with acute exacerbation of chronic non-obstructive bronchitis, and Enterobacteriaceae - in patients with COPD and pneumonia. The recent years have shown that, combined with other microorganisms, there can be detected pneumococci (p<0.05), H. influenzae, as well M. pneumoniae, while there have been fewer cases of enterococci and enterobacteria; as for non-filterable bacteria, they have been never detected again (p<0.05).Strains of H. influenzae maintained high sensitivity to aminopenicillins, including the protected ones. The antibiotic resistance possessed by Str. pneumoniae to aminopenicillins doubled (12.4% strains vs. 6.4% 3 years ago, p<0.05). The resistance to Co-trimoxazole and Ofloxacin was 27.9% and to macrolides it was 17.9%. Various representatives of the Enterobacteriaceae family maintained high sensitivity to aminopenicillins, second and third generation cephalosporins, fluoroquinolones.Of the 20 M. pneumoniae strains that were tested, 8 (40%) displayed resistance to one or more antimicrobials. The highest numbers of cases with resistance were detected to Ciprofloxacin (25%) and Erythromycin (20%). 10% strains of mycoplasma showed resistance to Doxycycline and Ofloxacin, while only 5% of mycoplasmas were identified as having non-sensitivity to Clarithromycin and Azithromycin.
The results of the research carried out in the recent years in comparison with the data of the previous years, call for reviewing of the standard approaches to the choice of antimicrobial agents in respiratory tract infections. In order to improve the standard of care, the choice of medicines should be based on a number of factors, namely the age, the severity of the respective pathological condition, previous antimicrobial use, and the level of care.
近年来,医院获得性和社区获得性呼吸道感染中的抗菌药物耐药性(AMR)呈逐步上升趋势。2006年发布的地区指南提出了药物治疗的标准方法,为斯塔夫罗波尔市和斯塔夫罗波尔地区医疗机构抗菌治疗的改善做出了重要贡献。与此同时,近年来对抗菌药物的敏感性发生了重大变化;此外,现在有了更新的抗生素。这证实了更新地区指南的必要性[1]。
确定门诊环境下下呼吸道(LRT)感染抗生素治疗标准化相关问题;评估与2003 - 2006年相比,2007 - 2012年地区医疗机构患者中导致LRT疾病的病原体谱随年龄和诊断的区域变化。
2007 - 2012年,我们按照方法指南[2],在临床药理学与药物治疗中心(俄罗斯斯塔夫罗波尔)的细菌学实验室对LRT感染患者的痰液进行了微生物学检查。将结果与2003 - 2006年7051份痰液样本的微生物学检查结果进行比较。使用算术平均值、标准误差和Student's t检验进行统计分析,涉及软件包STATISTICA 6.0。
在门诊实践中,一半的LRT感染患者被鉴定为感染肺炎链球菌。每五分之一接受检查的患者痰液中可分离出肠杆菌科成员,如克雷伯菌属(大多数情况下为肺炎克雷伯菌)、沙雷菌属、大肠杆菌和肠杆菌属。需要注意的是,几乎四分之一的患者被发现感染肺炎支原体。肺炎衣原体也经常被检测到(19%)。在所有成人社区获得性肺炎病例中,实际上80%都发现有肺炎链球菌、肺炎支原体和肺炎衣原体。从慢性阻塞性肺疾病(COPD)和慢性非阻塞性支气管炎患者的痰液中分离出流感嗜血杆菌和肺炎支原体的频率是其他患者的2 - 3倍。随着患者年龄的增加,无论诊断如何,肺炎球菌、流感嗜血杆菌和肠杆菌科各成员的比例上升,而支原体的比例下降。然而,即使在60岁以上的患者中,肺炎支原体在病原体总体谱中仍占很大比例,这表明需要进行微生物学监测,尤其是对于COPD患者。与前几年相比,接受抗生素治疗时仅35%的患者(之前为60%)进行了细菌学检查(p<0.05)。在先前接受β - 内酰胺类抗生素治疗的患者中,分离出的微生物结构中支原体显著流行。在14%的病例中检测到病原体关联,这是2 - 3年前发现率的一半。发现关联显示慢性非阻塞性支气管炎急性加重患者中流感嗜血杆菌更频繁出现,COPD和肺炎患者中肠杆菌科更频繁出现。近年来表明,与其他微生物合并时,可检测到肺炎球菌(p<0.05)、流感嗜血杆菌以及肺炎支原体,而肠球菌和肠杆菌的病例减少;至于不可滤过细菌,再也未检测到(p<0.05)。流感嗜血杆菌菌株对氨基青霉素(包括有保护基团的)保持高敏感性。肺炎链球菌对氨基青霉素的耐药性增加了一倍(12.4%的菌株 vs. 3年前的6.4%,p<0.05)。对复方新诺明和氧氟沙星的耐药性分别为27.9%,对大环内酯类的耐药性为17.9%。肠杆菌科各成员对氨基青霉素、第二代和第三代头孢菌素、氟喹诺酮类保持高敏感性。在检测的20株肺炎支原体菌株中,8株(40%)对一种或多种抗菌药物耐药。对环丙沙星(25%)和红霉素(20%)耐药的病例数最多。10%的支原体菌株对多西环素和氧氟沙星耐药,而只有5%的支原体对克拉霉素和阿奇霉素不敏感。
与前几年的数据相比,近年来的研究结果要求重新审视呼吸道感染中抗菌药物选择的标准方法。为了提高护理标准,药物选择应基于多个因素,即年龄